泊沙康唑在预防恶性血液病患者侵袭性真菌病中的应用研究

Study on the Application of Posaconazole in the Prevention of Invasive Mycosis in Patients with Malignant Hematological Diseases

目的:研究泊沙康唑在预防恶性血液病患者侵袭性真菌病中的应用效果。方法:选取我院2018年1月~2019年9月收治的50例恶性血液病患者,按照随机数余数分组法分为采取泊沙康唑预防的泊沙康唑组以及采取伊曲康唑预防的伊曲康唑组各25例,对两组预防效果进行对比。结果:泊沙康唑组预防治疗成功率为84.00%(21/25),显著高于伊曲康唑组的68.00%(17/25),侵袭性真菌病发生率为4.00%(1/25),显著低于伊曲康唑组的16.00%(4/25)(P<0.05);给药前两组炎性细胞因子差异无统计学意义(P>0.05),给药结束后均较本组给药前降低(P<0.05),组间比较泊沙康唑组均低于伊曲康唑组(P<0.05);泊沙康唑组治疗期间不良反应发生率为8.00%(2/25),伊曲康唑组治疗期间不良反应发生率为20.00%(5/25),两组不良反应发生率对比无统计学意义(P>0.05)。结论:在预防恶性血液病患者侵袭性真菌病中泊沙康唑效果更佳且安全性高,可作为优选用药方案推广使用。

Objective: To study the effect of posaconazole in the prevention of invasive mycosis in patients with malignant hematological diseases. Methods: Fifty patients with malignant hematological diseases treated in our hospital from January 2018 to September 2019 were randomly divided into Poisson conazole group(n=25) and itraconazole group(n=25). The preventive effects of the two groups were compared. Results: The success rate of preventive treatment in the posaconazole group was 84.00 %(21/25), which was significantly higher than the 68.00 %(17/25) of the itraconazole group, and the incidence of invasive fungal disease was 4.00 %(1/25),significantly lower than that 16.00 %(4/25) of the itraconazole group(P<0.05). There was no significant difference in inflammatory cytokines between the two groups before administration.(P>0.05), after the administration was lower than that before the administration of this group(P<0.05), compared between the groups, the posaconazole group was lower than the itraconazole group(P<0.05). The incidence of adverse reactions during the treatment of posaconazole group was 8.00 %(2/25), and the incidence of adverse reactions during treatment of itraconazole group was 20.00 %(5/25). The incidence of adverse reactions between the two groups was not statistically significant(P>0.05). Conclusion: Posaconazole has better effect and high safety in the prevention of invasive mycosis in patients with malignant hematology.